

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4915378

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
RONALD M. EVANS	11/15/2016
ANNETTE ATKINS	11/14/2016
RECEIVING PARTY DATA	
Name:	HOWARD HUGHES MEDICAL INSTITUTE
Street Address:	4000 JONES BRIDGE ROAD
City:	CHEVY CHASE
State/Country:	MARYLAND
Postal Code:	20815-6789
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15952516
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	503-595-5300
Email:	deborah.martin@klarquist.com
Correspondent Name:	S. RYBAK, PH.D./KLARQUIST SPARKMAN, LLP
Address Line 1:	121 SW SALMON STREET
Address Line 2:	ONE WORLD TRADE CENTER, SUITE 1600
Address Line 4:	PORTLAND, OREGON 97204-2988
ATTORNEY DOCKET NUMBER:	7158-95852-07
NAME OF SUBMITTER:	SHEREE LYNN RYBAK, PH.D.
SIGNATURE:	/Sheree Lynn Rybak/
DATE SIGNED:	04/13/2018
Total Attachments: 5	
source=Assignment (Evans & Atkins to HHMI)#page1.tif	
source=Assignment (Evans & Atkins to HHMI)#page2.tif	
source=Assignment (Evans & Atkins to HHMI)#page3.tif	
source=Assignment (Evans & Atkins to HHMI)#page4.tif	

ASSIGNMENT

This Assignment is from **Ronald M. Evans** residing at 1471 Cottontail Lane, La Jolla, California 92037 and **Annette Atkins** residing at 2730 Havasupai Avenue, San Diego, CA 92117 ("Inventors") to the **Howard Hughes Medical Institute**, a Delaware corporation (the "Institute"), having a place of business at 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789.

Recitals

WHEREAS, Inventors are employees of the Institute and, as a condition of their employment, have signed the Agreement appended to the Institute's Statement of Policy on Intellectual Property (the "Intellectual Property Agreement");

WHEREAS, pursuant to the Intellectual Property Agreement, Inventors have agreed (a) to assign to the Institute all rights they may acquire in any invention, discovery, improvement, or other intellectual property, whether or not patentable or copyrightable, developed directly or indirectly as a result of a program of research financed by Institute funds or by funds under the control of the Institute (each a "Subject Property") and (b) to execute any agreements that may be desired by the Institute in connection with such assignment;

WHEREAS, Inventors have, alone or with others, invented TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS, set forth in:

U.S. Provisional Patent Application No. 62/248,935, filed on October 30, 2015, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS";

PCT Patent Application No. PCT/US2016/059190, filed on October 27, 2016, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS";

(the "Invention"), and the Invention is a Subject Property; and

WHEREAS, Inventors seek to make a formal assignment of their interests in the Invention to the Institute, and the Institute desires the execution of a formal assignment of all of Inventors' right, title and interest in the Invention.

NOW THEREFORE, in consideration of the promises contained in and the acts performed and to be performed pursuant to the Intellectual Property Agreement and of other good and valuable consideration, the receipt of which is hereby acknowledged by Inventors, Inventors agree as follows:

1. Assignment. Inventors hereby assign to the Institute their entire right, title, and interest in the Invention; any United States patent applications and all corresponding foreign patent applications which are directed to the Invention, any and all patents issued therefrom; all United States or foreign division and continuation applications based on any of the foregoing applications, and any and all patents issued therefrom; and reissues or extensions of any such patents; and all claims which are directed to the Invention and which may be contained in continuation-in-part applications or in patents which issue therefrom.

2. Cooperation. Inventors agree to execute upon request such further assignments, documents, and other instruments as may be necessary or desirable to assign Inventors' entire right, title and interest in the Invention to the Institute and to assist the Institute (or others at the direction of the Institute) in applying for, obtaining, and enforcing patents, copyrights, or other rights in the United States and in any foreign country with respect to the Invention.


3. Parties. The terms and provisions of this Assignment shall inure to the benefit of the Institute and its successors and assigns and shall be binding on the Inventors and their heirs, personal representatives and assigns.

4. Warranty. Inventors warrant and represent that they have not entered into any assignment, contract, or understanding in conflict herewith, and that there is no other person or entity whose consent is required in order for the Inventors to make the assignment contained herein.

Date: 11/15/16

Inventor: 
RONALD M. EVANS


Witnessed by: Name MILLEN A. BROWN
Please Print or Type Name

Signature: 

Date: 11/14/16

Inventor: 
ANNETTE ATKINS


Witnessed by: Name MILLEN A. BROWN
Please Print or Type Name

Signature: 

The undersigned is authorized to sign this document on behalf of the **Howard Hughes Medical Institute**.

Executed at Chevy Chase, MD on the 17th day of November, 2016.

HOWARD HUGHES MEDICAL INSTITUTE

By 

Name (typed or printed) David E. Clapham, MD, PhD

Title (typed or printed) Vice President and Chief Scientific Officer

APPOINTMENT OF INVESTIGATOR AS AGENT

Appointment by the HOWARD HUGHES MEDICAL INSTITUTE (the "Institute") of RONALD M. EVANS, PhD., an employee of the Institute, as its agent for the purpose of assigning certain rights to the SALK INSTITUTE FOR BIOLOGICAL STUDIES ("Salk").

WHEREAS, the Institute and Salk collaborate in the active conduct of medical research pursuant to an Agreement between them dated as of January 1, 1990 (the "Agreement");

WHEREAS, pursuant to the Agreement, the Institute has agreed to assign to Salk the Institute's rights in Subject Property (as defined in the Agreement) in accordance with and subject to the conditions of the Agreement;

WHEREAS, research conducted pursuant to the Agreement by RONALD M. EVANS, PhD. while employed by the Institute at Salk has resulted in the invention of a certain Subject Property which is the subject of patent applications entitled

U.S. Provisional Patent Application No. 62/248,935, filed on October 30, 2015, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS"; and


PCT Patent Application No. PCT/US2016/059190, filed on October 27, 2016, entitled "TREATMENT OF STEROID-INDUCED HYPERGLYCEMIA WITH FIBROBLAST GROWTH FACTOR (FGF) 1 ANALOGS"; (the "Invention"), and the Invention is a Subject Property; and

WHEREAS, the Institute wishes RONALD M. EVANS, Ph.D. to act as its agent for the purpose of assigning to Salk the rights the Institute has in the Invention by reason of the research program conducted at Salk,

NOW, THEREFORE, the Institute hereby appoints RONALD M. EVANS, Ph.D. as its agent for the purpose of assigning the rights the Institute has or may acquire in the Invention to Salk in accordance with and subject to the conditions of the Agreement.


Executed November 17, 2016

HOWARD HUGHES MEDICAL INSTITUTE



By: David E. Clapham, MD, PhD Title: _____
Vice President and Chief Scientific Officer

ATTESTED:



By: Heidi E. Henning Title: Vice President and General Counsel